News
Displaying 61–70 of 506
-
Foundation News
The Foundation Fighting Blindness and the Retinal Degeneration (RD) Fund hosted their annual Investing in Cures Summit (ICS) on March 8 and 9, 2024, to highlight the progress in development of treatments and cures for the entire spectrum of retinal degenerative diseases.
-
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
Research NewsThe company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
Opus Reports Vision Improvements for Patients in LCA5 Gene Therapy Clinical Trial
Research NewsThe company plans to administer a higher dose of the emerging gene therapy to the next group of patients.
-
Foundation News
Collaboration will add a new multi-gene cohort of patients living with inherited retinal diseases. Data insights from the new study cohort will inform the future clinical trial design for BlueRock’s pipeline of cell therapies for treating blindness.
-
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Research NewsKnown as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
-
Foundation News
The May 9th gala will raise awareness and fund research leading to treatments and cures for blinding retinal diseases.
-
Foundation News
The free, online event on March 20, 2024, will feature presentations from Rachel Huckfeldt, MD, PhD, Mass Eye and Ear, and Rachelle Lin, OD, Ketchum University.
-
Research News
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
Foundation Fighting Blindness Launches GYROS, a Natural History Study for People with Gyrate Atrophy
Foundation NewsGyrate atrophy is an inherited retinal disease—causing progressive vision loss. GYROS results will help researchers design clinical trials for an emerging gyrate atrophy gene therapy.
-
Ascidian to Launch Clinical Trial for Stargardt Disease RNA Editing Therapy
Research NewsACDN-01 is the only genetic medicine entering clinical development for Stargardt disease.
